Biotech entity
fda-approval is the sole category represented across all 1 tracked stories. Alcon Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Timothy Stonesifer, all published on August 18, 2026.
Last mentioned: 6d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
fda-approval is the sole category represented across all 1 tracked stories. Alcon Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Timothy Stonesifer, all published on August 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Timothy Stonesifer. Shared-story counts are live from our verified record — not editorial picks.
Alcon posted 7% constant-currency sales growth and raised full-year core EPS guidance to 12-15% growth, but took a $402M noncash charge to discontinue PowerVision. Hims & Hers added branded weight-loss momentum with $753M revenue.
Timothy Stonesifer is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
